After bringing his total raise for Odyssey to $386M, Gary Glick is ready to start inking deals. Just watch
If there’s one thing Gary Glick excels at, it’s raising money for his startups. Even in this soured financial environment.
No sooner had he closed his whopping big launch round for Odyssey Therapeutics — announcing it late last year with $218 million brimming in his coffers — than he was off and running on the Series B. And today he’s taking the wraps off of the added cash — all $168 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.